• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Pulmonx Corporation

    2/25/25 4:53:21 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care
    Get the next $LUNG alert in real time by email
    S-8 1 pulmonx-sx822525.htm S-8 Document

    As filed with the U.S. Securities and Exchange Commission on February 25, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    Pulmonx Corporation
    (Exact name of Registrant as specified in its charter)
    Delaware77-0424412
    (State or other jurisdiction of
    Incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    700 Chesapeake Drive
    Redwood City, California 94063
    1-650-364-0400
    (Address of principal executive offices) (Zip code)
    Pulmonx Corporation 2020 Equity Incentive Plan
    Pulmonx Corporation 2020 Employee Stock Purchase Plan
    (Full titles of the plans)
    David Lehman
    General Counsel
    Pulmonx Corporation
    700 Chesapeake Drive
    Redwood City, California 94063
    (650) 364-0400
    (Name, address and telephone number, including area code, of agent for service)
    Copies to:
    Mark B. Weeks
    John T. McKenna
    Sepideh Mousakhani
    Cooley LLP
    3175 Hanover Street
    Palo Alto, California 94304
    (650) 843-5000
    Mehul Joshi
    Chief Financial Officer
    Pulmonx Corporation
    700 Chesapeake Drive
    Redwood City, California 94063
    (650) 364-0400
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☐Accelerated filer☐
    Non-accelerated filer☒Smaller reporting company☒
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐





    EXPLANATORY NOTE

    Pulmonx Corporation (the “Registrant”) is filing this registration statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) for the purpose of registering:

    •1,591,438 shares of its common stock, par value $0.001 per share (the “Common Stock”), under the Registrant’s 2020 Equity Incentive Plan (the “2020 Plan”) pursuant to an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2020 Plan on January 1, 2025, and

    •397,859 shares of Common Stock under the Registrant’s 2020 Employee Stock Purchase Plan (the “2020 ESPP”) pursuant to an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2020 ESPP on January 1, 2025.

    This Registration Statement relates to securities of the same class as, and in addition to, other securities for which earlier registration statements on Form S-8 were filed with the SEC on March 15, 2024 (File No. 333-277962), May 9, 2023 (File No. 333-271769), May 10, 2022 (File No. 333-264825), May 14, 2021 (File No. 333-256140) and October 1, 2020 (File No. 333-249187) (collectively, the “Prior Registration Statements”). Accordingly, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the 2020 Plan and 2020 ESPP, are incorporated by reference into this Registration Statement pursuant to General Instruction E to Form S-8.

    PART II

    ITEM 3.   INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
    The following documents filed by the Registrant with the SEC are incorporated by reference into this Registration Statement (other than information in such filings deemed, under SEC rules or otherwise, not to have been filed with the SEC):
    (a)the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 25, 2025; and
    (b)the description of the Registrant’s Common Stock which is contained in a registration statement on Form 8-A filed on September 24, 2020 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.3 of the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 15, 2021.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.




    ITEM 8.    EXHIBITS
    The exhibits to this Registration Statement are listed below:
    Incorporated by Reference
    Exhibit
    Number
    Description
    Schedule
    Form
    File NumberExhibitFiling Date
    4.1
    Amended and Restated Certificate of Incorporation of the Registrant.
    8-K001-395623.1October 5, 2020
    4.2
    Amended and Restated Bylaws of the Registrant.
    S-1/A333-2486353.4September 24, 2020
    4.3
    Form of Common Stock certificate of the Registrant.
    S-1/A333-2486354.1September 24, 2020
    5.1*
    Opinion of Cooley LLP.
    23.1*
    Consent of Cooley LLP (included in Exhibit 5.1).
    23.2*
    Consent of BDO USA, P.C., independent registered public accounting firm.
    24.1*
    Power of Attorney (included on the signature page of this Form S-8).
    99.1
    Pulmonx Corporation 2020 Equity Incentive Plan.
    S-8333-24918799.5October 1, 2020
    99.2
    Pulmonx Corporation 2020 Employee Stock Purchase Plan.
    S-8333-24918799.8October 1, 2020
    107*
    Filing Fee Table.
    * Filed herewith




    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Redwood City, State of California, on February 25, 2025.
    PULMONX CORPORATION
    By:/s/ Steven S. Williamson
    Name:
    Steven S. Williamson
    Title:President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven S. Williamson and Mehul Joshi, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.



    SignatureTitleDate
    /s/ Steven S. WilliamsonPresident, Chief Executive Officer and DirectorFebruary 25, 2025
    Steven S. Williamson(Principal Executive Officer)
    /s/ Mehul JoshiChief Financial OfficerFebruary 25, 2025
    Mehul Joshi(Principal Financial Officer and Principal Accounting Officer)
    /s/ Thomas W. BurnsDirectorFebruary 25, 2025
    Thomas W. Burns
    /s/ Richard FerrariDirectorFebruary 25, 2025
    Richard Ferrari
    /s/ Daniel P. FlorinDirectorFebruary 25, 2025
    Daniel Florin
    /s/ Glendon E. FrenchDirectorFebruary 25, 2025
    Glendon E. French
    /s/Georgia Garinois-MelenikiotouDirectorFebruary 25, 2025
    Georgia Garinois-Melenikiotou
    /s/ Dana G. Mead, Jr.DirectorFebruary 25, 2025
    Dana G. Mead, Jr.
    /s/ Tiffany SullivanDirectorFebruary 25, 2025
    Tiffany Sullivan

    Get the next $LUNG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LUNG

    DatePrice TargetRatingAnalyst
    7/31/2025$2.50Overweight → Neutral
    Piper Sandler
    3/10/2025$17.00Buy
    D. Boral Capital
    12/11/2024$17.00 → $7.50Buy → Neutral
    Citigroup
    6/4/2024$12.00Buy
    Lake Street
    2/23/2024$16.00 → $14.00Overweight → Equal Weight
    Wells Fargo
    9/5/2023$18.00Buy
    Craig Hallum
    2/27/2023$10.00 → $15.00Equal Weight → Overweight
    Wells Fargo
    1/3/2023$8.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $LUNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Radhakrishnan Srikanth claimed ownership of 181,219 shares (SEC Form 3)

    3 - Pulmonx Corp (0001127537) (Issuer)

    12/10/25 6:59:54 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Director Florin Daniel P sold $46,409 worth of shares (23,321 units at $1.99), decreasing direct ownership by 20% to 93,910 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    12/9/25 5:59:02 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    President and CEO French Glendon E. Iii sold $13,824 worth of shares (8,805 units at $1.57) and was granted 1,200,000 shares, increasing direct ownership by 416% to 1,477,324 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    12/3/25 7:51:47 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $LUNG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) (the "Company" or "Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the "Grant Date"), Pulmonx granted equity awards under its 2025 Inducement Plan (the "Inducement Plan") for an aggregate of 1,625,000 shares of Pulmonx's common stock to two individuals hired by Pulmonx in the fourth quarter of 2025, including Pulmonx's Chief Financial Officer and Chief Operating Officer, Derrick Sung. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new emp

    12/3/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx Reports Third Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2025 ended September 30, 2025. Recent Highlights Achieved worldwide revenue of $21.5 million in the third quarter of 2025, a 5% increase over the same period last year and an increase of 4% on a constant currency basisDelivered $7.5 million in international revenue in the third quarter of 2025, representing 15% year-over-year growth and an increase of 9% on a constant currency basisDelivered $14.0 million in U.S. revenue in the third quarter of 20

    11/12/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

    Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed Chief Operating Officer and Chief Financial OfficerSteve Williamson and Mehul Joshi have resigned from their respective roles at the Company, effective immediatelyPreliminary, unaudited third quarter 2025 revenue expected to be approximately $21.5 millionThird quarter 2025 financial results rescheduled to be released after the close of trading on Wednesday, November 12, 2025; Management to host conference call to discuss the results and the transition at 1:30 p.m. PT / 4:30 p.m.

    10/27/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $LUNG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Florin Daniel P bought $71,362 worth of shares (23,321 units at $3.06), increasing direct ownership by 25% to 117,231 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    6/5/25 8:39:08 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    8/22/24 6:41:17 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $LUNG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pulmonx downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Pulmonx from Overweight to Neutral and set a new price target of $2.50

    7/31/25 7:16:23 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    D. Boral Capital initiated coverage on Pulmonx with a new price target

    D. Boral Capital initiated coverage of Pulmonx with a rating of Buy and set a new price target of $17.00

    3/10/25 8:07:21 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx downgraded by Citigroup with a new price target

    Citigroup downgraded Pulmonx from Buy to Neutral and set a new price target of $7.50 from $17.00 previously

    12/11/24 7:54:19 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $LUNG
    SEC Filings

    View All

    SEC Form EFFECT filed by Pulmonx Corporation

    EFFECT - Pulmonx Corp (0001127537) (Filer)

    11/26/25 12:15:22 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form S-3/A filed by Pulmonx Corporation

    S-3/A - Pulmonx Corp (0001127537) (Filer)

    11/24/25 4:33:39 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Pulmonx Corporation

    S-8 - Pulmonx Corp (0001127537) (Filer)

    11/24/25 4:11:30 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $LUNG
    Leadership Updates

    Live Leadership Updates

    View All

    Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

    REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him

    4/2/24 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

    REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of

    2/21/24 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

    LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Service & Logistics at Mondelēz International, Inc., have been appointed to its Board of Directors effective December 8, 2023. "We are pleased to welcome Michael, Alissa and Andrea to our board of dir

    12/11/23 9:00:00 AM ET
    $HNST
    $LUNG
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    $LUNG
    Financials

    Live finance-specific insights

    View All

    Pulmonx Reports Third Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2025 ended September 30, 2025. Recent Highlights Achieved worldwide revenue of $21.5 million in the third quarter of 2025, a 5% increase over the same period last year and an increase of 4% on a constant currency basisDelivered $7.5 million in international revenue in the third quarter of 2025, representing 15% year-over-year growth and an increase of 9% on a constant currency basisDelivered $14.0 million in U.S. revenue in the third quarter of 20

    11/12/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

    Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed Chief Operating Officer and Chief Financial OfficerSteve Williamson and Mehul Joshi have resigned from their respective roles at the Company, effective immediatelyPreliminary, unaudited third quarter 2025 revenue expected to be approximately $21.5 millionThird quarter 2025 financial results rescheduled to be released after the close of trading on Wednesday, November 12, 2025; Management to host conference call to discuss the results and the transition at 1:30 p.m. PT / 4:30 p.m.

    10/27/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025

    REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Wednesday, October 29, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a

    10/15/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $LUNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/14/24 7:47:49 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/12/24 10:34:16 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/8/24 10:35:45 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care